| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 410.1 | 354.7 |
| Gross profit | 280.3 | 240.4 |
| Profit before tax | 56.3 | 52.3 |
| Net income | 42.3 | 45.9 |
| EPS (diluted, $ a share) | $1.07 | $1.17 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -7.8% |
|---|---|
| Revenue, year on year | +15.6% |
| Gross margin | 68.3% |
| Operating margin | 12.4% |
10-Q filed with the SEC, NYSE: PEN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Penumbra Inc: key numbers
- Share price
- $320.62Close, Nov 16
- Market cap
- $12.6B
- Shares outstanding
- 39.41MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Penumbra Inc
All →Penumbra Financial Results
Penumbra reported third quarter 2026 revenue of $410.1 million, a 15.6% increase year-over-year, driven by strong growth in its global thrombectomy business. The company reported net income of $42.3 million but noted it will not provide future guidance due to its pending acquisition by Boston Scientific Corporation. Operating expenses for the quarter included $7.1 million in acquisition-related costs.
- Counterparty
- Boston Scientific Corporation